MedTrace Logo

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

NCT07070934 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-17

No results posted yet for this study

Summary

This is a prospective study comparing anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients.

Conditions

Interventions

BIOLOGICAL

CAR-T

The T cells are genetically modified to expressa chimeric antigen receptor targeting BCMA andare infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg

BIOLOGICAL

ASCT

Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT).

Sponsors & Collaborators

  • Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Kailin Xu · The Affiliated Hospital oh Xuzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-07-15
Completion
2028-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070934 on ClinicalTrials.gov